RxDoctor Payments Data

Victor Salgado Bravo, MD

Cardiovascular Disease · Arecibo, PRNPI 1285842153

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Medtronic at 44.1% of the total.

$8,644in general payments, 2019–2025

Across 238 payments — averaging $36.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$811
  • Johnson & Johnson$635
  • Boehringer Ingelheim$598
  • Boston Scientific$580
  • E.r. Squibb & Sons, L.L.C.$432
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$8,610100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,644 in reported general payments places this provider in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,293
Medicare patients
30
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban684$500,351
VyndamaxTafamidis21$482,581
EliquisApixaban658$456,340
FarxigaDapagliflozin Propanediol286$188,271
EntrestoSacubitril/Valsartan157$126,636
JardianceEmpagliflozin149$112,212
Synjardy XrEmpagliflozin/Metformin Hcl131$92,823
TrulicityDulaglutide79$79,869
Trijardy XrEmpaglifloz/Linaglip/Metformin86$66,336
Soliqua 100-33Insulin Glargine/Lixisenatide54$50,948
Repatha SureclickEvolocumab74$45,135
Xigduo XrDapaglifloz Propaned/Metformin61$42,881
BrilintaTicagrelor70$36,680
JanumetSitagliptin Phos/Metformin Hcl43$31,052
GlyxambiEmpagliflozin/Linagliptin41$27,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$635$500,351684 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi, Tradjenta$598$331,303460 claims
AstraZenecaFarxiga, Brilinta$266$224,951356 claims
Lilly USA, LLCTrulicity, Mounjaro$147$104,546102 claims
MerckJanumet, Januvia, Janumet Xr$43$62,40385 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Arecibo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →